Pancreatic Cancer Clinical Trials in Chicago

Showing 81-100 of 165 trials

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

NCT05251038

This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy.

Pancreatic CancerUnresectable Pancreatic CancerMetastatic Pancreatic Cancer+1 more

Devalingam MahalingamStarted Sep 2022

Chicago, Illinois, United States

COMPLETEDPhase 32.2 miles

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

NCT03504423

A prospective, multicenter, open label, randomized phase III study to evaluate efficacy and safety of FFX versus CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years

Pancreatic Cancer Metastatic

Cornerstone Pharmaceuticals528 participantsStarted Nov 2018

Gilbert, Arizona, United States • Tucson, Arizona, United States • Duarte, California, United States +71 more locations

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Pancreatic Cancer Trials in Other Cities

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

Other Conditions in Chicago